An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

NCT01151410 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

208

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: Aliskiren
DRUG: Enalapril

Sponsor

Novartis Pharmaceuticals